Last $2.56 USD
Change Today -0.17 / -6.23%
Volume 92.1K
TRGT On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

targacept inc (TRGT) Snapshot

Open
$2.73
Previous Close
$2.73
Day High
$2.73
Day Low
$2.45
52 Week High
03/17/14 - $5.23
52 Week Low
10/24/14 - $2.25
Market Cap
87.8M
Average Volume 10 Days
245.8K
EPS TTM
$-1.11
Shares Outstanding
34.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TARGACEPT INC (TRGT)

Related News

No related news articles were found.

targacept inc (TRGT) Related Businessweek News

No Related Businessweek News Found

targacept inc (TRGT) Details

Targacept, Inc., a biopharmaceutical company, is engaged in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of nervous system and gastrointestinal/genitourinary diseases and disorders. Its product candidates in Phase IIb clinical trials include TC-5214 to treat overactive bladder; TC-1734 for the treatment of mild to moderate Alzheimer’s disease; and TC-5619 for the treatment of negative symptoms and cognitive dysfunction in schizophrenia. The company’s product candidates also comprise TC-6499 for the treatment for gastrointestinal disorders; TC-6987, a novel small molecule that modulates the activity of the a7 NNR; and AZD1446, a novel small molecule that modulates the activity of the a4ß2 NNR. It has a collaboration agreement with AstraZeneca AB to develop AZD1446 and earlier-stage compounds. Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina.

39 Employees
Last Reported Date: 03/14/14
Founded in 1997

targacept inc (TRGT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $687.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $140.7K
Compensation as of Fiscal Year 2013.

targacept inc (TRGT) Key Developments

Targacept, Inc. Appoints Mauri K. Hodges as Interim Vice President, Finance and Administration, Chief Financial Officer and Treasurer

On December 11, 2014, the Board of Directors of Targacept, Inc. appointed Mauri K. Hodges to serve on an interim basis as the company's Vice President, Finance and Administration, Chief Financial Officer and Treasurer, effective immediately. In this role, Ms. Hodges will also serve as company's principal accounting officer. Ms. Hodges, age 57, joined the company in 2000 and has served in several management roles, including as Vice President, Finance and Controller from 2007 to 2014 and, most recently, as Vice President, Human Resources and Corporate Systems.

Alan A. Musso Resigns as Senior Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Targacept, Inc., Effective December 11, 2014

On November 10, 2014, Alan A. Musso resigned from his position as Senior Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Targacept, Inc., effective December 11, 2014. Mr. Musso is resigning to pursue another professional opportunity in the biotechnology sector, and not due to any disagreement relating to Targacept's operations, policies or practices.

Targacept, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Targacept, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net operating revenues of $25,000. Operating loss was $4,988,000 against $13,146,000 a year ago. Loss before income taxes was $4,849,000 against $12,902,000 a year ago. Net loss was $4,860,000 or $0.14 basic and diluted per share against $12,902,000 or $0.38 basic and diluted per share a year ago. The lower net loss was primarily due to a decrease of $7.7 million in research and development expenses. For the nine months, the company reported net operating revenues of $148,000 against $3,536,000 a year ago. Operating loss was $24,983,000 against $33,908,000 a year ago. Loss before income taxes was $24,527,000 against $33,339,000 a year ago. Net loss was $27,995,000 or $0.83 basic and diluted per share against $33,339,000 or $0.99 basic and diluted per share a year ago. The lower net loss before income taxes for the 2014 period was principally due to a decrease of $12.3 million in operating expenses, partially offset by a decrease of $3.5 million in revenue recognized for payments received from collaborations. The decrease in net operating Revenue was primarily attributable to deferred revenue recognized during the 2013 period associated with its recently-terminated collaboration with AstraZeneca AB.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRGT:US $2.56 USD -0.17

TRGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amorfix Life Sciences Ltd C$0.21 CAD -0.01
Eli Lilly & Co $70.39 USD +0.23
Novartis AG SFr.92.35 CHF -1.20
Pfizer Inc $31.65 USD +0.23
View Industry Companies
 

Industry Analysis

TRGT

Industry Average

Valuation TRGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 359.0x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TARGACEPT INC, please visit www.targacept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.